Atlas Trials

A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Clinical trial NCT00191451 · COMPLETED

Trial details

NCT number
NCT00191451
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2004-04-01
Primary completion
2008-10-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.